Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics announced positive Phase III results from China for HRS9531, a once-weekly injectable GLP-1/GIP receptor dual agonist. The trial showed approximately 18% mean weight loss over 48 weeks, with 44% of participants losing at least 20% body weight. Most adverse events were mild or moderate and gastrointestinal in nature. Hengrui plans to file for approval in China, while Kailera prepares global clinical studies to evaluate higher doses and longer treatment duration. The drug joins a growing list of dual-acting obesity candidates leveraging gut hormone modulation.